ZLN005 is a potent and selective small molecule PGC-1α transcriptional activator. It stimulates the expression of PGC-1α and downstream genes in skeletal muscle cells, improving glucose utilization and fatty acid oxidation. Chronic oral administration of ZLN005 at 15 mg/kg per day to diabetic db/db mice increased PGC-1α and downstream gene transcription in skeletal muscle, increasing fat oxidation and improving glucose tolerance, pyruvate tolerance, and insulin sensitivity. PGC-1α is a tissue-specific and inducible transcriptional coactivator for several nuclear receptors and plays a key role in energy metabolism, hepatic gluconeogenesis, and cholesterol homoeostasis. ZLN005 is a useful chemical probe to study this target.
CAS Number: 49671-76-3
Molecular Weight: 250.34
Chemical Name: 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole
Appearance: white to off-white solid powder
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO up to 100 mM
Shipping Condition: Room temperature in continental US; may vary elsewhere.
Storage Condition: -20oCfor 3 years; 4oC 2 years
Shelf Life: ≥36 months if stored properly.
Stock Solution Storage: -80°C for 6 months -20°C for 1 month
Drug Formulation: This drug may be formulated in DMSO
HS Tariff Code: 2934.99.9001
How to use
ZLN005 was used at 10-20 µM final concentration in various in vitro assays.
ZLN005 was orally administrated in db/db mice at 15 mg/kg once per day for 6 weeks.
- Zhang LN, et al. Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. (2013) Diabetes. 62(4):1297-307.
Products are for research use only. Not for human use.